



JC09 PCT/PTO 14 JUN 2005.

Approved for use through 07/31/2006. OMB 0651-0031

	Approved for use unrough 07/3 1/2008, OMB 0651-003
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Hadarda Garage and Garage and Garage	J.S. Falcin and Hadelman Office, J.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, r	no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known		
				Application Number	Not yet known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			CLOSURE	Filing Date	Herewith	
			PPLICANT	First Named Inventor	Seetharama A. Acharya	
			ecoseary)	Art Unit	Not yet known	
				Examiner Name	Not yet known	
Sheet	1	of	1	Attorney Docket Number	96700/1023	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of					
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
/SL/	1	Juszczak et al., "UV Resonance Raman Study of β93-Modified Hemoglobin A: Chemical Modifier-Specific Effects and Added Influences of Attached Poly(ethylene glycol) Chains." Biochemistry 41:376-385 (January 2002). Manjula et al., "Site-Specific PEGylation of Hemoglobin at Cys-93(β): Correlation Between the Colligative Properties of the PEGylated Protein and the Length of the Conjugated PEG Chain." Bioconjugate Chem. 14:464-472 (2003).					
/SL/	2						
/SL/	3	Manjula et al., "Cys-99-ββ-Succinimidophenyl Polyethylene Glycol 200 Hemoglobin A." The Journal of Biological Chemistry 275, 8:5527-5534 (February 2000).					
/SL/	4	Vandegriff et al., "MP4, A New Nonvasoactive PEG-Hb Conjugate." Transfusion 43:509-516 (April 2003).					
	-						

Examiner Date	
Signature /Samuel Liu/ Considered 07/10	0/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.